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Abstract 
Protein expression of H, K and N-Ras was assessed in hormone sensitive and 
hormone refractory prostate tumour pairs from 61 patients by immunohistochemistry.  
Expression of H-Ras and K- Ras was not associated with any known clinical 
parameters.  In contrast an increase in N-Ras membrane expression in the transition 
from hormone sensitive to hormone refractory prostate cancer was associated with 
shorter time to relapse (p=0.01) and shorter disease specific survival (p=0.008).  In 
addition, patients with an increase in N-Ras membrane expression had lower levels of 
PSA at relapse (p=0.02) and expression correlated with phosphorylated MAP kinase 
(p=0.010) and proliferation index (Ki67, p=0.02).  These results suggest that in a 
subgroup patients N-Ras expression is associated with development of hormone 
refractory prostate cancer via activation of the MAP kinase cascade. 
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Introduction 
Prostate cancer is the second leading cause of cancer related deaths in the Western 
World, contributing to approximately 14% of overall cancer mortality[1].  It is 
extremely prevalent and 30,100 new cases are diagnosed in the UK each year, making 
it the most common male malignancy [1]. In the normal functioning prostate the rate 
of cell death is 1- 2% per day which is balanced by a proliferation rate of 1- 2% [2,5].  
The majority of prostate cancers diagnosed are dependent on the presence of 
androgens for growth and survival. Androgens, acting through the androgen receptor, 
modify transcription of androgen-regulated genes e.g. prostatic specific antigen (PSA) 
to promote the survival and proliferation of secretary epithelia. The main stay therapy 
for locally advanced or metastatic prostate cancer is therefore androgen ablation 
therapies, resulting in a reduction of androgens in the circulation and inhibition of 
tumour growth. Although 60-80% of patients initially respond to androgen ablation 
therapy, patients tend to relapse within a median time of 12-18 18-24 months.  Up-
regulation of growth factor signal transduction cascades provide one possible 
mechanism for the development of hormone refractory prostate cancer that appears to 
have escaped androgen control [8,9,29]. 
 
The mechanisms of resistance to androgen ablation therapy are not fully understood 
although in vitro studies have demonstrated that activation of signal transduction 
cascades such as Raf/MAPK and PI3K/Akt pathways may be involved, both these 
pathways may be activated directly by the 21kDa Ras family of proteins, key 
mediators of growth factor pathway activity[13].   The RAS gene family encode 21 
Kdalton proteins of which there are four isoforms; H-Ras, N-Ras and two isoforms of 
K-Ras (A and B). A hyper-variable region of 25 amino acids in the C-terminal 
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accounts for the differences in function and properties of these Ras isoforms[16]. 
Inactive Ras is located in the cytosol; activation requires a series of post-translational 
modifications and translocation to the membrane. Post-translational modifications of 
Ras slightly differ between the four isoforms. All are farnesylated and H-Ras and N-
Ras then become palmitoylated and transit through the Golgi to the plasma membrane 
(PM) whereas K-Ras does not undergo palmitoylation and follows a yet unknown 
route to the plasma membrane. Once located at the inner face of the plasma membrane 
Ras isoforms function as GTPases interacting with downstream signalling cascades. 
Gene mutations in the RAS family are associated with multiple cancers including 
breast, colorectal [7], and prostate [31,28,26]. Ras proteins are over-expressed and 
activated in a high frequency of prostate cancer tumours and are associated with the 
development of hormone refractory disease, possibly due to gene amplification[10]. 
Ras over-expression correlates with prostate cancer progression and is associated with 
the formation of metastases [4]. When LNCaP cells are serially passaged in low 
steroid medium H-Ras expression increases, as LNCaP cells become hormone 
resistant[30]. In addition when mutated hRAS is transfected into a hormone sensitive 
cell line, MAP kinase activity, a down stream target of Ras, is elevated and hormone 
dependence decreases[30].  It is hypothesised that wild-type Ras is chronically 
activated by autocrine and paracrine growth factor stimulation, resulting in activation 
of down stream pathways associated with the development of hormone refractory 
disease e.g. MAP kinase pathways.  In human prostate tumours, phosphorylated MAP 
kinase expression increases with tumour stage and grade and is over-expressed in 
hormone refractory disease[30] and down regulates androgen receptor mediated 
promoter activity[25].  We have therefore hypothesized that Ras promotes the 
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development of hormone refractory prostate cancer via the MAP kinase-signalling 
cascade.   
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Materials and Methods 
Patient cohort 
Ethical approval for this study was obtained from the multi-centre Research Ethics 
Committee (MREC Scotland) and relevant Local Research Committees (LRECs). All 
tumours had patient identification removed, including block number and hospital 
number, and were coded to anonymise the database. Sixty-one prostate cancer patients 
were selected for study, each patient had both hormone sensitive and hormone 
refractory tumour available for analysis.  All patients in the cohort were newly 
diagnosed and were not identified from a watchful waiting programme. Therefore 
each patient in the cohort had received no prior treatment before receiving androgen 
deprivation therapy (25 patients had sub capsular orchidectomy, 36 patients received 
GnRH analogues, 3 had both), in addition all patients that received GnRH also 
received anti androgens. All patients in the cohort responded to androgen deprivation 
therapy and tumours were defined as hormone sensitive or responsive to androgen 
deprivation therapy if patient serum PSA levels decreased by at least 50% whilst 
undergoing androgen deprivation therapy.  Patients were then defined as having 
biochemical relapse if PSA subsequently rose by 10% or more, during hormone 
ablation therapy.  The hormone sensitive tumour samples were obtained by either a 
TURP or a TRUS guided biopsy and hormone refractory tumour samples were 
obtained by TURP following failure of hormone deprivation therapy (and to treat 
clinical symptoms of bladder outflow obstruction).  PSA profile and full clinical 
follow up was available for each patient, in addition expression of phosphorylated Akt 
(serine 473) and Ki67 were available for each tumour from a previous study[11].  Akt 
was scored using the weighted histoscore method[11] and Ki67 scored using the 
proliferation index method[17]. 
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Western blot 
Before commencing immuno staining, western blotting was carried out to confirm 
antibody specificity (figure 1). Cell lines were lysed for 5 minutes at 4°C using cell 
lysis buffer (cell signalling technology Beverly, USA) with 1mM PMSF added 
immediately before use. Protein samples (50ug) were resolved by SDS-PAGE and 
transferred to nitrocellulose membrane at 100V for one hour. After transfer 
membranes were blocked in 5% Marvel in Tween-TBS (TTBS) for one hour and 
incubated with Hras, KRas, NRas (IgG1 Ab, F155, Santa Cruz Biotechnology, CA, 
USA, 2µg/ml) or phosphorylated MAP kinase antibody 1µg/ml (cell signalling 
technology Beverly, USA) diluted in 10 ml 5% marvel in TTBS over night at 4°C. 
This was followed by incubating in horseradish peroxidase-labelled anti-mouse Ig 
0.5µg/ml (cell signalling technology Beverly, USA) diluted in 10 ml 5% marvel in 
TTBS for one hour at room temperature. Detection was performed using enhanced 
chemiluminescence detection kit (Amersham Pharmacia Biotech, Buckinghamshire, 
UK). 
Immunohistochemistry  
Tumour expression of H, K, N-Ras and phosphorylated MAP kinase (Threonine 
202/Tyrosine 204) was determined in paraffin embedded tissue sections (5µm) by 
Immunohistochemistry (IHC). Sections were dewaxed in xylene and rehydrated 
through graded alcohols prior to blocking endogenous peroxidase in 3% hydrogen 
peroxide. Antigen retrieval was performed by heating tissue sections under pressure in 
TE Buffer (1mM EDTA, 5mM Tris, pH 8.0) for five minutes in a microwave.  
Sections were blocked and incubated in K-Ras (IgG2 Ab, 234-4.2, Sigma, Missouri, 
USA, 20µg/ml), H-Ras (IgG1 Ab, F235, Santa Cruz Biotechnology, CA, USA, 
20µg/ml), N-Ras (IgG1 Ab, F155, Santa Cruz Biotechnology, CA, USA, 20µg/ml) 
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and phosphorylated MAP kinase (human p44 Map Kinase,  Cell Signaling 
Technology, USA, 4 µg/ml) primary antibody overnight at 4oC. In each run a negative 
isotype matched control was included. H, N-Ras and phosphorylated MAP kinase was 
visualised using Dako LSAB+ Kit (Dako) and the chromagen 3,3’-diaminobenzidine 
(DAB, Vector Laboratories, CA, USA) and K-Ras was detected using the Super 
Sensitive Non-Biotin HRP Detection System (BioGenex, CA, USA).  In addition, 
phosphorylated Akt (serine 473) and Ki67 were available for each tumour from a 
previous study.  All antibodies used in this study had their specificity confirmed by 
western blotting (Fig.1). 
 
Histoscore Method 
Protein expression level was determined using the weighted histoscore method  
(Hscore method) by two independent observers[21,19]. Histoscores were calculated 
from the sum of (1 x the % of cells staining weakly positive)+ (2x the % of cells 
staining moderately positive)+ (3 x the % of cells staining strongly positive) with a 
maximum histoscore of 300. The inter-class correlation coefficient (ICCC) between 
each observer for each of the proteins was confirmed to measure consistency between 
observers. All ICCC values were > 0.7, which is classed as excellent as; an ICCC of 1 
indicates identical scores. The mean of two observers scores were used for analysis. 
Changes in staining between hormone sensitive and hormone refractory cases were 
defined as an increase or decrease out with the 95% confidence interval for the 
difference in inter-observer variation (i.e. the mean difference between the histoscore 
that each observer assigns for protein expression plus 2SD).   
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Statistical Analysis 
All statistical analysis was performed using the SPSS version 9.0 for Windows. 
Protein expression data was not normally distributed and is shown as median and 
interquartile ranges. Wilcoxon signed Rank tests were used to compare Ras protein 
expression between hormone sensitive prostate cancer (HSPC) and hormone 
refractory prostate cancer (HRPC) tumours. Survival analysis was conducted using 
the Kaplan–Meier method and curves were compared with the log rank test. Hazard 
ratios (HR) were calculated using Cox regression analysis. Correlations for 
continuous variables were calculated using Spearman Rank Correlation Coefficients, 
correlations for categorized variable were calculated using Chi square test and non 
parametric tests were conducted using Mann Whitney U test.    A value of p < 0.05 
was considered statistically significant.  
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Results 
Sixty one patients were diagnosed with locally advanced (42) or metastatic prostate 
cancer (19). The median age at diagnosis was 70  (inter quartile range (IQR) 66-74) 
and the median PSA at diagnosis was 19 µg/ml (IQR 6-42 µg/ml), median time to 
relapse was 24 months (IQR 12-60 months) and median time to death from relapse 
was 12 months (IQR 12-36 months).   
Gleason sum at diagnosis ranged from 4 to 10 and high Gleason sum was associated 
with shorter time to relapse (p=0.05).  In addition high Gleason sum at diagnosis 
(p=0.017), presence of metastases at diagnosis (p=0.005) and presence of metastases 
at relapse (p=0.001) were associated with shorter disease specific survival.  In 
contrast, low PSA (<4ng/ml) at relapse was associated with shorter time to relapse 
(p<0.0001) and shorter disease specific survival (p=0.0002), suggesting patients with 
low PSA levels at relapse have poorer prognosis, possibly due to having escaped 
androgen control (Fig.2). 
Although membrane and cytoplasmic expression was observed for all Ras isoforms, 
cytoplasmic expression was stronger and more commonly observed than membrane 
expression. However, as membrane localisation can be employed as a surrogate 
marker of Ras activation, membrane and cytoplasmic expression were individually 
assessed.  Cytoplasmic expression levels of any Ras isoforms in this cohort was not 
associated with time to biochemical relapse and only high N-Ras membrane 
expression levels correlated with shorter disease specific survival (p=0.01).  Twenty 
five percent of patients (15/61) were classified as having high N-Ras expression in 
their hormone sensitive tumours, their median survival period was 5.5 years compared 
to 12.5 years for those with low N-Ras expression, the hazard ratio for high N-Ras 
expression was calculated to be 3.12 (95% C.I. 1.19-8.18).  N-Ras expression was not 
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associated with Gleason at diagnosis (p=0.91) or presence of metastases at diagnosis 
(p=0.30). 
However, the strength of this cohort was that matched hormone refractory tumours 
were also available for each patient in addition to their hormone sensitive tumour.  We 
were therefore able to establish if expression levels significantly changed in the 
transition from hormone sensitive to hormone refractory disease.  When median 
protein expression levels in the hormone sensitive and hormone refractory tissue were 
compared no statistically significant increase was observed for any Ras isoforms at 
any location with the exception of N-Ras located at the membrane (p=0.04).   The 
median expression of N-Ras located at the membrane in hormone sensitive tumours 
was 0 (IQR 0-20) increasing to 20 (IQR 0-80) in the hormone refractory tumours.  
This increase in median expression was modest, however the nature of the cohort 
enabled us to investigate the increase on an individual patient basis, patients were then 
subdivided into those whose matched tumours exhibited an increase compared to 
those whose tumours exhibited a decrease or no change in expression in the transition 
from hormone sensitive to hormone refractory disease.  Eleven percent (7/61) of 
patients tumours exhibited an increase in N-Ras membrane expression and when you 
consider only those patients with an increase in N-Ras expression at the membrane, 
the median histoscore for membrane expression rose from 0 (0-17.5) to 75 (57.5-87.5) 
histoscore units (Fig.3, p=0.018)). 
 
Subgroup analysis revealed that changes in expression levels of H-Ras or K-Ras in the 
transition from hormone sensitive to hormone refractory disease were not associated 
with any clinical parameters. However, an increase in N-Ras membrane expression 
with the development of hormone refractory disease was significantly associated with 
shorter time to biochemical relapse (Fig.4a, p= 0.01). The median time to relapse for 
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those patients who had an increase in N-Ras membrane expression was 1.97 years 
(IQR 0.2-3.7), compared to 2.47 years (IQR 1.35-3.59) for those patients who had a 
decrease/no change in N-ras membrane expression. The hazard ratio for patients who 
had a significant increase in N-Ras membrane expression was 2.8 (95% C.I. 1.2-6.3). 
The significant association with increased N-Ras membrane expression also translated 
into shorter disease specific survival (Fig.4b, p=0.008). The median survival period 
for those patients who had an increase in N-Ras membrane expression was 3.37 years 
(IQR 2.18-4.56), compared to 6.57 years (IQR 5.63-7.51) for those patients who had a 
decrease/no change in N-Ras membrane expression.  Therefore those patients with an 
increase in membrane N-Ras expression had a median survival disadvantage of more 
than 3 years, the hazard ratio for patients who had a significant increase in N-Ras 
membrane expression was 3.2 (95% C.I. 1.3-7.9).  Those patients with an increase in 
N-Ras membrane expression had significantly lower PSA levels at relapse than those 
patients with no change/decrease in N-Ras membrane expression (Fig.4c, p=0.02) and 
significantly higher levels of phosphorylated MAP kinase expression in the hormone 
refractory tissue (Fig.4d, p=0.04).  Median phosphorylated MAP kinase expression 
was 81 (IQR 50-106) for the tumours with decrease/no change in N-Ras expression 
compared to 117 (IQR 107-145) for the tumours with an increase in N-Ras 
expression. 
 
When protein expression levels of the Ras family were correlated with expression 
levels of phosphorylated Akt473 (marker of PI3K pathway activation), phosphorylated 
MAP kinase202/204 (marker of MAP kinase pathway activation), androgen receptor and 
Ki67 (proliferation index), N-Ras at the membrane in the hormone refractory tumours 
correlated with phosphorylated MAP kinase and Ki67 but not with phosphorylated 
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Akt or androgen receptor (Table 1).  These results suggest that in hormone refractory 
prostate cancer N-Ras may activate the MAP kinase cascade to induce proliferation 
independent of androgens and the androgen receptor. 
 
Discussion 
In the current study we have demonstrated that low PSA at relapse is associated with 
poorer outcome both in terms of length of time to biochemical relapse and also with 
disease specific survival.  This suggests that when there is clear evidence of 
symptomatic relapse (bladder outflow obstruction and presence of metastases), but 
low PSA levels, prostate cancer tumour growth is controlled independent of the 
androgen receptor.  Activation of Ras has recently been demonstrated to stimulate 
androgen independent prostate cancer cell line growth and inhibit PSA expression via 
Ras-responsive element binding protein –1 (RREB-1)[22,20,25], therefore suggesting 
that up-regulation of Ras may be involved in progression from the hormone sensitive 
to hormone refractory state.  
The aim of the current project is to establish if Ras expression is up-regulated in 
clinical hormone refractory prostate cancer and therefore determine if it has a role as a 
possible therapeutic target and/or biomarker in hormone refractory prostate cancer.  In 
the current cohort cytoplasmic expression of H, K and N Ras was observed in both 
hormone sensitive and hormone refractory tumours, however membrane expression 
(which may be used as a surrogate marker of activation) was expressed at lower levels 
and most commonly observed for N-Ras only.  Previous studies report that Ras 
proteins are activated in prostate cancer tumours and are associated with the 
development of hormone refractory disease, however these studies did not investigate 
expression at an isoform specific level [4,15].  In the current study, although 
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cytoplasmic expression was observed for all 3 isoforms, it was not associated with 
any known clinical parameters or patient outcome measures for K or H-Ras.  In 
contrast, a significant increase in N-Ras membrane expression (activation) was 
observed with development of hormone refractory disease and in a sub-cohort of 
patients was associated with shorter time to relapse and shorter disease specific 
survival.  In addition, N-Ras membrane expression was associated with low levels of 
PSA at relapse, high phosphorylated MAP kinase expression and high proliferation 
index.  Suggesting that activation of N-Ras may stimulate prostate cancer 
proliferation via the MAP kinase cascade, independent of androgen receptor 
activation.   
The difference in the function of the Ras isoforms may be due to their ability to 
activate different downstream effectors [16]. K-Ras has shown to be more effective in 
activating Raf-1 whereas H-Ras is more effective in activating PI3K[18,3].  H-Ras 
has recently been reported to stimulate ARE-gene transcription in prostate cancer 
lines, resulting in an increase in PSA expression and cellular proliferation[6], however 
in the current cohort N-Ras expression is associated with low PSA expression.  This is 
consistent with a recent study that reports that Ras can down regulate androgen 
receptor mediated promoter activity and suppress expression of PSA protein via 
RREB-1 interaction with the androgen receptor [25]. We therefore hypothesise that 
N-Ras may be influencing down-regulation of PSA via RREB-1 and stimulating 
prostate cancer growth in an androgen receptor independent manner via activation of 
the MAP kinase cascade. In vitro studies demonstrate that N-Ras stimulates prostate 
cancer cell proliferation (LNCaP cells) via the MAP kinase cascade[14] and we have 
previously linked activation of the MAP kinase cascade with development of hormone 
refractory disease using the current patient cohort[24,23]. Both an increase in Raf-1 
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and MAP kinase expression are significantly associated with a shorter time to 
biochemical relapse and MAP kinase expression was also associated with reduced 
overall survival.  
Therefore Ras, in particular N-Ras may be a potential target to inhibit signal 
transduction cascades driving hormone refractory prostate cancer. Interestingly, 
previous studies have been devoted to the design of Ras inhibitors, including the 
design of farnesyltransferase inhibitors (FTIs) to block Ras processing and membrane 
anchorage and also the design of compounds that resemble the farnesylcystine of Ras 
to inhibit Ras- membrane association[27]. Recent studies demonstrate that Ras 
inhibition results in growth arrest and death of androgen independent prostate cancer 
cells therefore suggesting that Ras may be employed as a therapeutic target for 
hormone refractory prostate cancer [22,12].   
In summary this study provides evidence that N-Ras, but not K- or H-Ras, may have a 
role in the development of hormone refractory prostate cancer.  
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Table 1 Positive correlations between Ras family members and downstream proteins
 Akt MAP kinase Androgen 
Receptor 
Ki67 
Hormone sensitive     
H-Ras (membrane) 
p value 
r2 
 
X 
 
X 
 
X 
 
X 
H-Ras (cytoplasmic) 
p value 
r2 
 
X 
 
X 
 
X 
 
X 
K-Ras (membrane) 
p value 
r2 
 
0.009 
0.367 
 
X 
 
X 
 
X 
K-Ras (cytoplasmic) 
p value 
r2 
 
X 
 
X 
 
X 
 
X 
N-Ras (membrane) 
p value 
r2 
 
0.038 
0.281 
 
0.033 
0.288 
 
X 
 
X 
N-Ras (cytoplasmic) 
p value 
r2 
 
X 
 
X 
 
X 
 
X 
Hormone insensitive     
H-Ras (membrane) 
p value 
r2 
 
X 
 
X 
 
X 
 
0.014 
0.375 
H-Ras (cytoplasmic) 
p value 
r2 
 
X 
 
X 
 
X 
 
X 
K-Ras (membrane) 
p value 
r2 
 
X 
 
X 
 
X 
 
X 
K-Ras (cytoplasmic) 
p value 
r2 
 
X 
 
X 
 
X 
 
X 
N-Ras (membrane) 
p value 
r2 
 
X 
 
0.01 
0.381 
 
X 
 
0.02 
0.390 
N-Ras (cytoplasmic) 
p value 
r2 
 
X 
 
X 
 
X 
 
X 
 
Table 1 shows significant correlations between Ras family member expression (as 
determined by histoscore) and phosphorylated Akt, phosphorylated MAP kinase, 
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androgen receptor and Ki67 (proliferation index) assessed by Spearman’s Rank 
Correlation test. 
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Figure Legends 
Fig.1.  Photographs of H, K and N-Ras and phosphorylated MAP kinase protein expression 
in hormone refractory prostate cancer tumours.  Western blots for the appropriated 
antibodies are also included to confirm specificity.   
K-Ras specificity was assessed using cell lysates from KRNK cells, which are a normal rat 
kidney [NRK] cell line transformed by Kirsten murine sarcoma virus.  
H-Ras specificity was assessed using cell lysates from MDAMB 453 breast cancer cell line, 
which is known to exhibit an increase in H-Ras expression in response to heregulin 
treatment, the band labelled UT453 are untreated MDAMB 453 cells and the band labelled 
1nMHRG453 are MDAMB 453 cells treated with 1 nM heregulin.  A small increase in 
expression of H-Ras is noted in response to heregulin stimulation.   
N-Ras specificity was assessed using cell lysates from MCF-7 breast cancer cell lines, 
which are known to exhibit an increase in N-Ras expression in response to heregulin 
treatment, the band labelled UTMCF-7 are untreated MCF-7 cells and the band labelled 
1nMHRGMCF-7 are MCF-7 cells treated with 1 nM heregulin.  A small increase in 
expression of N-Ras is noted in response to heregulin stimulation.   
Phosphorylated MAP kinase specificity was assessed using cell lysates from MCF-7 breast 
cancer cell lines, which are known to exhibit an increase in N-Ras expression in response to 
oestrogen treatment, the band labelled control is purified phosphorylated MAP kinase 
protein, the band labelled UT are untreated MCF-7 cells and the band labelled 10nME2 are 
MCF-7 cells treated with 10 nM oestrogen.  A small increase in expression of 
phosphorylated MAP kinase is noted in response to oestrogen stimulation. 
Fig.2. Kaplan Meier plots demonstrating that those patients with low PSA (<4ng/ml) at 
relapse (dotted line) have (a) shorter time to relapse (p<0.0001) and (b) shorter disease 
specific survival (p=0.0002) than those patients with high PSA at relapse (solid line). 
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Fig.3. Patients who demonstrated a significant rise (>43 histoscore units) in N-Ras 
membrane expression with the development of hormone refractory prostate cancer. 
Membrane expression is highlighted using an arrow.  The median histoscore for the 
hormone sensitive samples is 0 (IQR 0-17.5) compared to 75 (IQR 57.5-87.5) in the 
hormone refractory tumours (p=0.018).  
Fig.4. Kaplan Meier plots demonstrating that those patients with an increase in N-Ras 
membrane expression (dotted line) have (a) shorter time to relapse (p=0.01) and (b) shorter 
disease specific survival (p=0.008) than those patients with a decrease/no change in N-Ras 
membrane expression (solid line).  (c) Box plot showing PSA levels at relapse of patients 
with a decrease/no change in N-Ras expression compared to those with an increase in N-
Ras expression (p=0.02).  (d) Box plot showing phosphorylated MAP kinase expression 
levels in hormone refractory tumours of patients with a decrease/no change in N-Ras 
expression compared to those with an increase in N-Ras expression (p=0.04). 
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